Insights into angiogenesis in non-small cell lung cancer: Molecular mechanisms, polymorphic genes, and targeted therapies

Recent Patents on Anti-Cancer Drug Discovery

Volumn 7, Issue 1, 2012, Pages 118-131

  de Mello, Ramon Andrade ^a,e   Costa, Bruno M ^b   Reis, Rui M ^b,c   Hespanhol, Venceslau ^d,e  

^a PORTUGUESE ONCOLOGY INSTITUTE   (Portugal)

^b UNIVERSITY OF MINHO   (Portugal)

^c BARRETOS CANCER HOSPITAL   (Brazil)

^d HOSPITAL DE SÃO JOÃO   (Portugal)

^e University of Porto   (Portugal)

Author keywords

Angiogenesis; Antineoplastic drug combination; Biological markers; Neovascularization; Non small cell lung cancer; Pathology; Polymorphism; Vascular endothelial growth factor

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; FIBROBLAST GROWTH FACTOR RECEPTOR; GEFITINIB; GEMCITABINE; MOTESANIB; NOTCH DELTA LIKE LIGAND 4; PACLITAXEL; PANITUMUMAB; PLACEBO; PLACENTAL GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN RET; REGULATOR PROTEIN; RILOTUMUMAB; SORAFENIB; SUNITINIB; TIVANTINIB; UNCLASSIFIED DRUG; VANDETANIB; VASCULOTROPIN; VASCULOTROPIN RECEPTOR; XL 184;

DRUG RESPONSE; GENETIC POLYMORPHISM; HUMAN; LUNG NON SMALL CELL CANCER; MOLECULAR PATHOLOGY; MOLECULARLY TARGETED THERAPY; MUTATOR GENE; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; TUMOR VASCULARIZATION; VASCULOTROPIN GENE;

EID: 83455233831     PISSN: 15748928     EISSN: None     Source Type: Journal    
DOI: 10.2174/157489212798357994     Document Type: Review

References (117)

1. Schrump D, Giaccone G, Kelsey K, Marks L. Non Small Cell Lung Cancer. In: DeVita V, Lawrence T, Rosenberg S, Weinberg R, DePinho R, editors. DeVita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 8thed. Philadelphia: Lippincott Williams & Wilkins 2008: 896-939.
2. Fauci A, Braunwald E, Kasper D, Hauser S, Longo D, Jameson J, et al. Harrison's Principles of Internal Medicine. 17thed. New York McGraw-Hill Medical Publishing Division 2008: 551-62.
3. Guo X, Chen Y, Xu Z, Qian Y, Yu X. Prognostic significance of VEGF-C expression in correlation with COX-2, lymphatic microvessel density, and clinicopathologic characteristics in human non-small cell lung cancer. Acta Biochim Biophys Sin (Shanghai) 2009; 41(3): 217-22.
4. Herbst R, Heymach J, Lippman S. Molecular origins of cancer. N Engl J Med 2008; 359 (13): 1367-80.
5. Abeloff MD, Armitage JO, Niederhuber JE, Kastan MB, McKenna WG. Abeloff's Clinical Oncology. 4thed. Philadelphia: Churchill Livingstone; 2008: 1327-46.
6. Alberg A, Brock M, Samet J. Epidemiology of lung cancer: looking to the future. J Clin Oncol 2005; 23(14): 3175-85.
7. [Sculier J, Chansky K, Crowley J, Van Meerbeeck J, Goldstraw P. The impact of additional prognostic factors on survival and their relationship with the anatomical extent of disease expressed by the 6th Edition of the TNM Classification of Malignant Tumors and the proposals for the 7th Edition. J Thorac Oncol 2008; 3(5): 457-66.
8. Fong K, Minna J. Molecular biology of lung cancer: Clinical implications. Clin Chest Med 2002; 23(1): 83-101.
9. Kumar S, Guleria R, Singh V, Bharti A, Mohan A, Das B. Efficacy of plasma vascular endothelial growth factor in monitoring firstline chemotherapy in patients with advanced non-small cell lung cancer. BMC cancer 2009; 9(1): 421.
10. Bremnes R, Camps C, Sirera R. Angiogenesis in non-small cell lung cancer: The prognostic impact of neoangiogenesis and the cytokines VEGF and bFGF in tumours and blood. Lung Cancer. 2006; 51(2): 143-58.
11. Reck M, von Pawel J, Zatloukal P, Ramlau R, Gorbounova V, Hirsh V, et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol 2009; 27(8): 1227-34.
12. Kerbel R. Tumor angiogenesis. N Engl J Med 2008; 358(19): 2039-49.
13. Folkman J. Tumor Angiogenesis: From Bench to Bedside. In: Marmé D, Fusenig N, editors. Tumor Angiogenesis: Basic concepts and cancer therapy. 8thed. Berlin: Springer 2008: 3-28.
14. Herbst R, Onn A, Sandler A. Angiogenesis and lung cancer: Prognostic and therapeutic implications. J Clin Oncol 2005; 23(14): 3243-46.
15. Folkman J. Tumor angiogenesis: Therapeutic implications. N Engl J Med 1971; 285: 1182-86.
16. Dvorak H. Vascular permeability factor/vascular endothelial growth factor: A critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol 2002; 20(21): 4368-80.
17. Ferrara N, Henzel W. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem Biophys Res Commun 1989; 161(2): 851-58.
18. Semenza G. Hydroxylation of HIF-1: Oxygen sensing at the molecular level. Physiology (Bethesda) 2004; 19: 176-82.
19. Kasahara Y, Tuder R, Taraseviciene-Stewart L, Le Cras T, Abman S, Hirth P, et al. Inhibition of VEGF receptors causes lung cell apoptosis and emphysema. J Clin Invest 2000;106(11):1311-19.
20. Juttner S, Wissmann C, Jons T, Vieth M, Hertel J, Gretschel S, et al. Vascular endothelial growth factor-D and its receptor VEGFR-3: Two novel independent prognostic markers in gastric adenocarcinoma. J Clin Oncol 2006; 24(2): 228-40.
21. González R, Leyva A, Melo R, Moreira R, Pessoa C, Farias R, et al. Método para estudo in vivo da angiogênese: Indução de neovascularização na córnea de coelho. Acta Cir Bras 2000; 15(3): 168-73.
22. Duda D, Jain R, Willett C. Antiangiogenics: The potential role of integrating this novel treatment modality with chemoradiation for solid cancers. J Clin Oncol 2007; 25(26): 4033-42.
23. Noguera-Troise I, Daly C, Papadopoulos N, Coetzee S, Boland P, Gale N, et al. Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis. Nature 2006; 444(7122): 1032-37.
24. Sainson R, Harris A. Anti-Dll4 therapy: Can we block tumour growth by increasing angiogenesis? Trends Mol Med 2007; 13(9): 389-95.
25. Bonnesen B, Pappot H, Holmstav J, Skov BG. Vascular endothelial growth factor A and vascular endothelial growth factor receptor 2 expression in non-small cell lung cancer patients: Relation to prognosis. Lung Cancer 2009; 66(3): 314-8.
26. Yuan A, Yu C, Luh K, Chen W, Lin F, Kuo S, et al. Quantification of VEGF mRNA expression in non-small cell lung cancer using a real-time quantitative reverse transcription-PCR assay and a comparison with quantitative competitive reverse transcription- PCR. Lab Invest 2000; 80(11): 1671-80.
27. Jain R, Duda D, Willett C, Sahani D, Zhu A, Loeffler J, et al. Biomarkers of response and resistance to antiangiogenic therapy. Nat Rev Clin Oncol 2009; 6(6): 327-38.
28. Jubb A, Oates A, Holden S, Koeppen H. Predicting benefit from anti-angiogenic agents in malignancy. Nat Rev Cancer 2006; 6(8): 626-35.
29. Laack E, Kohler A, Kugler C, Dierlamm T, Knuffmann C, Vohwinkel G, et al. Pretreatment serum levels of matrix metalloproteinase-9 and vascular endothelial growth factor in nonsmall- cell lung cancer. Ann Oncol 2002; 13(10): 1550-7.
30. Nikolinakos P, Altorki N, Yankelevitz D, Tran H, Yan S, Rajagopalan D, et al. Plasma cytokine and angiogenic factor profiling identifies markers associated with tumor shrinkage in early-stage non-small cell lung cancer patients treated with pazopanib. Cancer Res 2010; 70(6): 2171-9.
31. Dowlati A, Gray R, Sandler A, Schiller J, Johnson D. Cell Adhesion molecules, vascular endothelial growth factor, and basic fibroblast growth factor in patients with non-small cell lung cancer treated with chemotherapy with or without bevacizumab: An Eastern Cooperative Oncology Group Study. Clin Cancer Res 2008; 14(5): 1407-12.
32. Horn L, Sandler AB. Angiogenesis in the treatment of non-small cell lung cancer. Proc Am Thorac Soc 2009; 6(2): 206-17.
33. Sandler A, Gray R, Perry M, Brahmer J, Schiller J, Dowlati A, et al. Paclitaxel-carboplatin alone or with bevacizumab for nonsmall- cell lung cancer. N Engl J Med 2006; 355(24): 2542-50.
34. Blumenschein G, Reckamp K, Stephenson G, O'Rourke T, Gladish G, McGreivy J, et al. Phase 1b study of motesanib, an oral angiogenesis inhibitor, in combination with carboplatin/paclitaxel and/or panitumumab for the treatment of advanced non-small cell lung cancer. Clin Cancer Res 2010; 16(1): 279-90.
35. Socinski M, Novello S, Brahmer J, Rosell R, Sanchez J, Belani C, et al. Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer. J Clin Oncol 2008; 26(4): 650-6.
36. Hanrahan E, Lin H, Kim E, Yan S, Du D, McKee K, et al. Distinct patterns of cytokine and angiogenic factor modulation and markers of benefit for vandetanib and/or chemotherapy in patients with nonsmall- cell lung cancer. J Clin Oncol 2010; 28(2): 193-201.
37. Oliveira P, Colaço A, Chaves R, Guedes-Pinto H, De-La-Cruz PL, Lopes C. Chemical carcinogenesis. An Acad Bras Cienc. 2007;79:593-616.
38. Chiang A, Massague J. Molecular basis of metastasis. N Engl J Med 2008; 359(26): 2814-23.
39. Rathinavelu, A., Dakshanamurthy, S., Pattabiraman, N. Specific inhibitors for vascular endothelial growth factor receptors. US7875603 (2011).
40. Hanna N, Von Pawel J, Reck M, Scagliotti G. Carboplatin/paclitaxel with/without sorafenib in chemonaive patients with stage IIIB-IV non-small cell lung cancer (NSCLC): Interim analysis (IA) results from a randomized phase III trial (ESCAPE). J Thorac Oncol 2008; 3: S268.
41. Scagliotti G, von Pawel J, Reck M, Cupit L, Cihon F, DiMatteo S, et al. Sorafenib plus carboplatin/paclitaxel in chemonaive patients with stage IIIB-IV non-small cell lung cancer (NSCLC): Interim analysis (IA) results from the phase III, randomized, double-blind, placebo-controlled, ESCAPE (Evaluation of Sorafenib, Carboplatin, and Paclitaxel Efficacy in NSCLC) trial. J Thor Oncol 2008; 3: S97-S98.
42. Natale R, Bodkin D, Govindan R, Sleckman B, Rizvi N, Capo A, et al. Vandetanib versus gefitinib in patients with advanced nonsmall- cell lung cancer: Results from a two-part, double-blind, randomized phase II study. J Clin Oncol 2009; 27(15): 2523-9.
43. Lee J, Hirsh V, Park K, Qin S, Blajman C, Perng R, et al. Eds. Vandetanib versus placebo in patients with advanced non-small cell lung cancer (NSCLC) after prior therapy with an EGFR tyrosine kinase inhibitor (TKI): A randomized, double-blind phase III trial (ZEPHYR). American Society of Clinical Oncology - 10th annual meeting, Chicago, USA, (2010).
44. Herbst R, Sun Y, Eberhardt W, Germonpré P, Saijo N, Zhou C, et al. Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): A double-blind, randomised, phase 3 trial. Lancet Oncol 2010; 11(7): 619-26.
45. Blumenschein Jr G, Gatzemeier U, Fossella F, Stewart D, Cupit L, Cihon F, et al. Phase II, multicenter, uncontrolled trial of singleagent sorafenib in patients with relapsed or refractory, advanced non-small-cell lung cancer. J Clin Oncol 2009; 27(26): 4274-80.
46. Gutierrez M, Kummar S, Allen D, Turkbey B, Choyke P, Wright J, et al. A phase II study of multikinase inhibitor sorafenib in patients with relapsed non-small cell lung cancer (NSCLC). American Society of Clinical Oncology - 8th annual meeting, Chicago, USA, (2008).
47. Adjei A, Molina J, Mandrekar S, Marks R, Reid J, Croghan G, et al. Phase I trial of sorafenib in combination with gefitinib in patients with refractory or recurrent non-small cell lung cancer. Clin Cancer Res 2007; 13(9): 2684-91.
48. th annual meeting, Chicago, USA, (2006).
49. th annual meeting, Chicago, USA, (2007).
50. th annual meeting, Chicago, USA, (2007).
51. Korpanty G, Smyth E, Sullivan L, Brekken R, Carney D. Antiangiogenic therapy in lung cancer: Focus on vascular endothelial growth factor pathway. Exp Biol Med 2010; 235(1): 3-9.
52. Schiller J, Larson T, Ou S, Limentani S, Sandler A, Vokes E, et al. Efficacy and safety of axitinib in patients with advanced non-smallcell lung cancer: Results from a phase II study. J Clin Oncol 2009; 27(23): 3836-41.
53. O'reilly, M.S., Folkman, J.M., Abrams, G.S. Therapeutic antiangiogenic endostatin compositions. US7867975 (2011).
54. Reck M, Kaiser R, Eschbach C, Stefanic M, Love J, Gatzemeier U, et al. A phase II double-blind study to investigate efficacy and safety of two doses of the triple angiokinase inhibitor BIBF 1120 in patients with relapsed advanced non-small-cell lung cancer. Ann Oncol 2011; doi: 10.1093/annonc/mdq618.
55. Araujo A, Ribeiro R, Azevedo I, Coelho A, Soares M, Sousa B, et al. Genetic polymorphisms of the epidermal growth factor and related receptor in non-small cell lung cancer: A review of the literature. Oncologist 2007; 12(2): 201-10.
56. Zhu C, da Cunha Santos G, Ding K, Sakurada A, Cutz J, Liu N, et al. Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR. 21. J Clin Oncol 2008; 26(26): 4268-75.
57. Miller V, Riely G, Zakowski M, Li A, Patel J, Heelan R, et al. Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib. J Clin Oncol 2008; 26(9): 1472-8.
58. Choong N, Salgia R, Vokes E. Key signaling pathways and targets in lung cancer therapy. Clin Lung Cancer 2008; 8(suppl 2): 52-60.
59. Adjei A, Hidalgo M. Intracellular signal transduction pathway proteins as targets for cancer therapy. J Clin Oncol 2005; 23(23): 5386-403.
60. Toschi L, Cappuzzo F. Understanding the new genetics of responsiveness to epidermal growth factor receptor tyrosine kinase inhibitors. Oncologist 2007; 12(2): 211-20.
61. Rosell R, Cuello M, Cecere F, Santarpia M, Reguart N, Felip E, et al. Usefulness of predictive tests for cancer treatment. Bull Cancer 2006; 93(8): E101-E08.
62. Sholl L, Xiao Y, Joshi V, Yeap B, Cioffredi L, Jackman D, et al. EGFR Mutation is a better predictor of response to tyrosine kinase inhibitors in non-small cell lung carcinoma than FISH, CISH, and immunohistochemistry. Am J Clin Pathol 2010; 133(6): 922-34.
63. Zhang Z, Stiegler A, Boggon T, Kobayashi S, Halmos B. EGFRmutated lung cancer: A paradigm of molecular oncology. Oncotarget 2010; 1(7): 497-514.
64. Shepherd F, Rodrigues Pereira J, Ciuleanu T, Tan E, Hirsh V, Thongprasert S, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005; 353(2): 123-32.
65. Lynch T, Bell D, Sordella R, Gurubhagavatula S, Okimoto R, Brannigan B, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350(21): 2129-39.
66. Ichihara S, Toyooka S, Fujiwara Y, Hotta K, Shigematsu H, Tokumo M, et al. The impact of epidermal growth factor receptor gene status on gefitinib-treated Japanese patients with non-smallcell lung cancer. Int J Cancer 2007; 120(6): 1239-47.
67. Lind J, Dingemans A, Groen H, Thunnissen F, Bekers O, Heideman D, et al. A Multicenter Phase II study of erlotinib and sorafenib in chemotherapy-naïve patients with advanced non-small cell lung cancer. Clin Cancer Res 2010; 16(11): 3078-87.
68. Takano T, Ohe Y, Sakamoto H, Tsuta K, Matsuno Y, Tateishi U, et al. Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer. J Clin Oncol 2005; 23(28): 6829-37.
69. Hirsch F, Varella-Garcia M, McCoy J, West H, Xavier A, Gumerlock P, et al. Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: A Southwest Oncology Group Study. J Clin Oncol 2005; 23(28): 6838-85.
70. Tracy S, Mukohara T, Hansen M, Meyerson M, Johnson B, Jänne P. Gefitinib induces apoptosis in the EGFRL858R non-small-cell lung cancer cell line H3255. Cancer Res 2004; 64(20): 7241-4.
71. Krause D, Van Etten R. Tyrosine kinases as targets for cancer therapy. N Engl J Med 2005; 353(2): 172-87.
72. Mok T, Wu Y, Thongprasert S, Yang C, Chu D, Saijo N, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009; 361(10): 947-57.
73. Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010; 362(25): 2380-8.
74. Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurutani J, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): An open label, randomised phase 3 trial. Lancet Oncol 2010; 11(2): 121-28.
75. Cappuzzo F, Ciuleanu T, Stelmakh L, Cicenas S, Szczésna A, Juhász E, et al. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: A multicentre, randomised, placebocontrolled phase 3 study. Lancet Oncol 2010; 11(6): 521-9.
76. Pao W, Miller V, Politi K, Ricly G, Somwar R, Zakowski M, et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PloS Med 2005; 2(3): 225-35.
77. Toschi L, Cappuzzo F. Clinical implications of MET gene copy number in lung cancer. Future Oncol 2010; 6(2): 239-47.
78. Saavedra, O.M., Claridge, S.W., Zhan, L., Raeppel, F., Vaisburg, A., Raeppel, S., Deziel, R., Mannion, M., Zhou, N. Z., Isakovic, L. Inhibitors of VEGF receptor and HGF receptor signaling. US7790729 (2010).
79. th annual meeting, Chicago, USA, (2010).
80. th annual meeting, Chicago, USA, (2010).
81. Shinomiya, N., Vande Woude, G.F. c-met siRNA adenovirus vectors inhibit cancer cell growth, invasion and tumorigenicity. US7872117 (2011).
82. th annual meeting, Chicago, USA, (2006).
83. Kiura K, Nakagawa K, Shinkai T, Eguchi K, Ohe Y, Yamamoto N, et al. A randomized, double-blind, phase IIa dose-finding study of vandetanib (ZD6474) in Japanese patients with non-small cell lung cancer. J Thorac Oncol 2008;3(4):386-93.
84. Heymach J, Johnson B, Prager D, Csada E, Roubec J, Pesek M, et al. Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non small-cell lung cancer. J Clin Oncol 2007; 25(27): 4270-7.
85. Heymach JV, Paz-Ares L, De Braud F, Sebastian M, Stewart DJ, Eberhardt WEE, et al. Randomized phase II study of vandetanib alone or with paclitaxel and carboplatin as first-line treatment for advanced non-small-cell lung cancer. J Clin Oncol 2008; 26(33): 5407-15.
86. Sridhar S, Shepherd F. Targeting angiogenesis: A review of angiogenesis inhibitors in the treatment of lung cancer. Lung Cancer 2003; 42(2): 81-91.
87. Lee S, Woll P, Rudd R, Ferry D, O'Brien M, Middleton G, et al. Anti-angiogenic therapy using thalidomide combined with chemotherapy in small cell lung cancer: A randomized, doubleblind, placebo-controlled trial. J Nat Cancer Inst 2009; 101(15): 1049-57.
88. Reck M, von Pawel J, Zatloukal P, Ramlau R, Gorbounova V, Hirsh V, et al. Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous nonsmall- cell lung cancer: Results from a randomised phase III trial (AVAiL). Ann Oncol 2010; 21(9): 1804-9.
89. Pirker R. Bevacizumab in lung cancer: Hurdles in clinical development. Lancet Oncol 2010; 11(8): 703-4.
90. th annual meeting, Chicago, USA (2009).
91. th annual meeting, Chicago, USA (2008).
92. Hong, K., Guo, L.S.S., Tseng, Y.L., Song, H.L., Chang, P.C., Shih, S.F. Anti-VEGF monoclonal antibody. US7740844 (2010).
93. Fuh, G., Gerber, H.P., Liang, W.C., Fellouse, F.A., Sidhu, S.S., Wiesmann, C. Anti-VEGF antibodies. US7691977 (2010).
94. Rosen P, Sweeney C, Park D, Beaupre D, Deng H, Leitch I, et al. A Phase Ib study of AMG 102 in combination with bevacizumab or motesanib in patients with advanced solid tumors. Clin Cancer Res 2010; 16(9): 2677-87.
95. Moss R, Bothos J, Filvaroff E, Merchant M, Eppler S, Yu W, et al. Phase Ib dose-escalation study of MetMAb, a monovalent antagonist antibody to the receptor MET, in combination with bevacizumab in patients with locally advanced or metastatic solid tumors. American Society of Clinical Oncology - 10th annual meeting, Chicago, USA, (2010).
96. Bates, D., Harper, S. VEGF isoforms and their use as antiangiogenic, anti-vasodilatory, anti-permeability and antiproliferative agents. US7820178 (2010).
97. Stassen, J.M., Carmeliet, P., Collen, D. Anti-PLGF antibody. US7875704 (2011).
98. Laino C. NSCLC: MetMAb+ erlotinib extends survival in subset of lung cancer patients. Oncology Times 2010; 32(24): 38-39.
99. Ciardiello F, Jezdic S. New insights on personalized cancer treatments: A report from the ESMO Congress. Expert Rev Anticancer Ther 2011; 11(1): 21-23.
100. Dy G, Adjei A. Novel targets for lung cancer therapy: Part I. J ClinOncol 2002; 20(12): 2881-94.
101. Jain L, Vargo CA, Danesi R, Sissung TM, Price DK, Venzon D, et al. The role of vascular endothelial growth factor SNPs as predictive and prognostic markers for major solid tumors. Mol Cancer Ther 2009; 8(9): 2496-508.
102. Vidaurreta M, Sánchez-Muñoz R, Veganzones S, Rafael S, Gutiérrez M, de la Orden V, et al. Vascular endothelial growth factor gene polymorphisms in patients with colorectal cancer. Rev Esp Enferm Dig 2010; 102(1): 20-31.
103. Zhai R, Liu G, Zhou W, Su L, Heist R, Lynch T, et al. Vascular endothelial growth factor genotypes, haplotypes, gender, and the risk of non-small cell lung cancer. Clin Cancer Res 2008; 14(2): 612-7.
104. Balasubramanian S, Brown N, Reed M. Role of genetic polymorphisms in tumour angiogenesis. Br J Cancer 2002; 87(10): 1057-65.
105. Howell W, Bateman A, Turner S, Collins A, Theaker J. Influence of vascular endothelial growth factor single nucleotide polymorphisms on tumour development in cutaneous malignant melanoma. Genes Immun 2002; 3(4): 229-32.
106. McCarron S, Edwards S, Evans P, Gibbs R, Dearnaley D, Dowe A, et al. Influence of cytokine gene polymorphisms on the development of prostate cancer. Cancer Res 2002; 62(12): 3369-72.
107. Koukourakis M, Papazoglou D, Giatromanolaki A, Bougioukas G, Maltezos E, Siviridis E. VEGF gene sequence variation defines VEGF gene expression status and angiogenic activity in non-small cell lung cancer. Lung Cancer 2004; 46(3): 293-98.
108. Heist RS, Zhai R, Liu G, Zhou W, Lin X, Su L, et al. VEGF polymorphisms and survival in early-stage non-small-cell lung cancer. J Clin Oncol 2008; 26(6): 856-62.
109. Bieniasz M, Oszajca K, Eusebio M, Kordiak J, Bartkowiak J, Szemraj J. The positive correlation between gene expression of the two angiogenic factors: VEGF and BMP-2 in lung cancer patients. Lung Cancer. 2009; 66(3): 319-26.
110. Dong J, Dai J, Shu Y, Pan S, Xu L, Chen W, et al. Polymorphisms in EGFR and VEGF contribute to non-small cell lung cancer survival in a Chinese Population. Carcinogenesis 2010; 31(6): 1080-6.
111. Lee SJ, Lee SY, Jeon HS, Park SH, Jang JS, Lee GY, et al. Vascular endothelial growth factor gene polymorphisms and risk of primary lung cancer. Cancer Epidemiol Biomarkers Prev 2005; 14(3): 571-5.
112. Masago K, Fujita S, Kim Y, Hatachi Y, Fukuhara A, Nagai H, et al. Effect of vascular endothelial growth factor polymorphisms on survival in advanced stage non small cell lung cancer. Cancer Sci 2009; 100(10): 1917-22.
113. Watson C, Webb N, Bottomley M, Brenchley P. Identification of polymorphisms within the vascular endothelial growth factor (VEGF) gene: Correlation with variation in VEGF protein production. Cytokine 2000; 12(8): 1232-35.
114. Shahbazi M, Fryer A, Pravica V, Brogan I, Ramsay H, Hutchinson I, et al. Vascular endothelial growth factor gene polymorphisms are associated with acute renal allograft rejection. J Am Soc Nephrol 2002; 13(1): 260-4.
115. Stevens A, Soden J, Brenchley P, Ralph S, Ray D. Haplotype analysis of the polymorphic human vascular endothelial growth factor gene promoter. Cancer Res 2003; 63(4): 812-6.
116. Inoue A, Kobayashi K, Usui K, Maemondo M, Okinaga S, Mikami I, et al. First-line gefitinib for patients with advanced non-smallcell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy. J Clin Oncol 2009; 27(9): 1394-400.
117. Brundage M, Davies D, Mackillop W. Prognostic factors in nonsmall cell lung cancer. Chest 2002; 122(3): 1037-57.